---
layout: default
title: Fulvestrant
parent: 僅模型預測 (L5)
nav_order: 156
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fulvestrant: From Unconfirmed Original Indication to HIV Infectious Disease

## One-Sentence Summary

Fulvestrant (DB00947) has no confirmed original indication in this evidence pack — both the approved-use record and the mechanism of action are flagged as data gaps (DG001, DG002).
The TxGNN model predicts it may be effective for **HIV infectious disease**,
but this direction is currently supported by **0 clinical trials** and only **1 tangentially related publication**, with the model's own scoring stage recommending **Hold**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no license records or indication text in this evidence pack (see data gap DG001) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% (rank 1374) |
| Evidence Level | L5 |
| Market Status | Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for fulvestrant in this evidence pack (data gap DG002, High severity). Without MOA data, and without any confirmed original indication (data gap DG001, Blocking severity — TFDA label retrieval still pending), it is not possible to construct a pharmacologically grounded argument for why fulvestrant would work in HIV infection.

The model's own rationale for this candidate is explicit about this weakness: the single supporting publication is a multi-cohort cross-omics analysis of HTLV-1-associated myelopathy (HAM) — a distinct retrovirus-driven neuroinflammatory disease — not a direct study of HIV or of fulvestrant's estrogen receptor (ER) pathway in relation to HIV replication or immune modulation. No mechanistic bridge between ER antagonism and HIV pathophysiology is established in the available evidence.

Given this, the high TxGNN score most plausibly reflects proximity between nodes in the underlying knowledge graph rather than a validated pharmacological signal. This candidate should be treated as hypothesis-generating only, not as evidence of therapeutic potential.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Cross-omics Analysis (Tier 3) | Research Square | Multi-cohort (epi)genomic analysis of HTLV-1-associated myelopathy (HAM), a neuroinflammatory disorder related to but distinct from HIV; does not directly study fulvestrant or HIV infection. Relevance to the predicted indication is unconfirmed (marked "pending"). |

---

## Norway Market Information

No authorized products found — `total_licenses = 0` and the licenses list is empty in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all flagged as data gaps or "not found" in this evidence pack.)

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence level is L5 (model prediction only) — there are zero clinical trials and a single, indirectly relevant publication that does not study HIV or fulvestrant directly. Combined with two unresolved data gaps (missing TFDA safety label — Blocking; missing MOA — High), this candidate cannot advance to a safety or mechanistic evaluation stage.

**To proceed, the following is needed:**
- TFDA label / package insert (warnings, contraindications) — required before any S1 safety screening (DG001)
- Confirmed mechanism of action via DrugBank API query (DG002)
- Confirmation of fulvestrant's actual original approved indication(s), currently absent from this pack
- Literature or preclinical studies directly linking ER antagonism (or fulvestrant specifically) to HIV viral replication or immune regulation
- If no further direct evidence emerges, this candidate should remain deprioritized relative to higher-evidence candidates (e.g., rank 2, "multiple endocrine neoplasia," which is backed by dozens of fulvestrant-containing Phase 2/3 breast cancer trials, though note that disease label itself warrants a relevance check against those trials)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

